Drug Trial Radar · NCT05769777
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
999
Actual
Start
Apr 3, 2023
Primary completion
Jun 11, 2031
Study completion Jun 11, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD. The study duration per participant will be up to 284 weeks, including: * A screening period of up to 2 to 4 weeks * An open label treatment period of up to 268 weeks (approximately 5 years) * A post-treatment safety follow-up period of at least 20 weeks after the last dose administration (last IMP administration at Week 264) The planned number of visits will be 35 visits.
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline up to end of study (EOS) (Week 284)
- Percentage of participants who experienced Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Baseline up to EOS (Week 284)
Locations
174 sites in 25 countries. Site status is shown where the registry gives one.
Allervie Clinical Research - Birmingham- Site Number : 8400050
Birmingham, Alabama
Research Solutions of Arizona- Site Number : 8400020
Litchfield Park, Arizona
Dermatology Trial Associates- Site Number : 8400027
Bryant, Arkansas
University Dermatology Trials- Site Number : 8400052
Newport Beach, California
Children's Hospital Colorado - Aurora- Site Number : 8400041
Aurora, Colorado
IMMUNOe International Research Centers - Centennial- Site Number : 8400024
Centennial, Colorado
Renaissance Research and Medical Group- Site Number : 8400006
Cape Coral, Florida
Florida Pharmaceutical Research and Associates- Site Number : 8400018
Miami, Florida
Miami Clinical Research Tower- Site Number : 8400036
Miami, Florida
Florida Research Center- Site Number : 8400011
Miami, Florida
Clinical Research Trials of Florida- Site Number : 8400054
Tampa, Florida
Advanced Medical Research - Atlanta- Site Number : 8400044
Atlanta, Georgia
Georgia Skin & Cancer Clinic- Site Number : 8400048
Savannah, Georgia
Sneeze Wheeze & Itch Associates- Site Number : 8400002
Normal, Illinois
Kentucky Advanced Medical Research- Site Number : 8400014
Murray, Kentucky
The Derm Institute of West Michigan- Site Number : 8400043
Caledonia, Michigan
Michigan Dermatology Institute - Livonia- Site Number : 8401010
Livonia, Michigan
Michigan Dermatology Institute - Waterford- Site Number : 8400010
Waterford, Michigan
Dermatology Research Center of Oklahoma- Site Number : 8400035
Tulsa, Oklahoma
The Children's Hospital of Philadelphia- Site Number : 8400009
Philadelphia, Pennsylvania
Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400053
San Antonio, Texas
Private Practice - Dr. Marthe N. Dika- Site Number : 8400022
Burlington, Wisconsin
Investigational Site Number : 0320008
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Argentina
Investigational Site Number : 0320009
Buenos Aires, Argentina
Investigational Site Number : 0320005
Buenos Aires, Argentina
Investigational Site Number : 0320022
General Pico, La Pampa Province, Argentina
Investigational Site Number : 0320006
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0320007
Rosario, Santa Fe Province, Argentina
Investigational Site Number : 0360002
Kogarah, New South Wales, Australia
Investigational Site Number : 0360001
Sydney, New South Wales, Australia
IDERJ - Instituto de Dermatologia e Estética do Brasil- Site Number : 0760004
Rio de Janeiro, Brazil
Centro de Pesquisas da Clínica IBIS- Site Number : 0760002
Salvador, Estado de Bahia, Brazil
Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760022
Curitiba, Paraná, Brazil
Pontifica Universidade Catolica do Parana- Site Number : 0760023
Curitiba, Paraná, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760005
Porto Alegre, Rio Grande do Sul, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760008
Ribeirão Preto, São Paulo, Brazil
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.